Press Releases

2017 Net Sales of Inavir ® in Japan Exceeded ¥20 Billion, Triggering USD $5 Million Milestone Payment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 20, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 19, 2018-- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of Brant Biehn as Senior Vice President,

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 16, 2018-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that new preclinical data on its intranasal Chikungunya

SOUTH SAN FRANCISCO, Calif., April 2, 2018 — Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive officer of Vaxart , will

Issued Claims Cover High Yield Production Process of Phase 2 Antiviral SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT) a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will present clinical data from two Phase 1 studies of its

Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc. Combined Company Renamed Vaxart, Inc. and Will Begin Trading Under New Symbol NASDAQ: VXRT SOUTH SAN FRANCISCO, CA and ATLANTA, Feb. 13, 2018 — Vaxart, Inc. (NASDAQ: VXRT) today announced the completion of its merger with Aviragen

CAS Group Supports Improved Deal Company Currently has Sufficient Votes to Approve Merger ATLANTA , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that the reconvened Special Meeting of Stockholders has been further adjourned to 10:00 AM, EST on February

Aviragen Stockholders to Own 49% of Combined Company, Up from 40% Under the Previous Agreement

Board of Directors Unanimously Recommends that Aviragen Stockholders Vote FOR the Vaxart Merger

Reiterates Transaction Represents Best Path Forward for Aviragen and ALL Stockholders CAS Group Has Not Articulated a Clear Plan and Has Now Changed its Stance to Emphasize Teslexivir (BTA074) ATLANTA , Jan. 31, 2018 (GLOBE NEWSWIRE) --   Aviragen Therapeutics, Inc.

Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study